|
Gender (M:F)
|
15:5
|
|---|
|
Age (years)
|
73 [62–77]
|
|
HBV positivity (%)
|
1 (5%)
|
|
HCV positivity (%)
|
6 (30%)
|
|
NASH (%)
|
3 (15%)
|
|
Alcohol abuse (%)
|
7 (35%)
|
|
MELD score
|
7 [6–10]
|
|
AFP, (ng/mL)
|
7.5 [3.2–23.5]
|
|
CEA, (ng/mL)
|
1.7 [1.1–3.3]
|
|
CA 19.9 (UI/mL)
|
16.9 [9.9–19.3]
|
|
Tumor number (%)
| |
|
- 1
|
14 (70%)
|
|
- 2
|
4 (20%)
|
|
- 3
|
2 (10%)
|
|
Satellites lesions (%)
|
3 (15%)
|
|
Tumor max diameter (cm)
|
4.3 [3–10.8]
|
|
Edmonson-Steiner grading (%)
|
|
- G1
|
4 (20%)
|
|
- G2
|
12 (60%)
|
|
- G3
|
4 (20%)
|
|
Microvascular invasion (%)
|
7 (35%)
|
|
Tumor staging (%)
|
|
- T1
|
7 (35%)
|
|
- T2
|
7 (35%)
|
|
- T3
|
3 (15%)
|
|
- T4
|
3 (15%)
|
|
Tumor recurrence (%)
|
10 (50%)
|
|
Recurrence time, (months)
|
25.4 [7.4–33.5]
|
- Continuous variables are expressed by median [interquartile range], Categorical variables by percentage
- AFP alphafetoprotein; CA 19.9 Carbohydrate Antigen 19.9, CEA carcinoembryonic antigen, HBV hepatitis B virus, HCV hepatitis C virus, NASH non alcoholic steatohepatitis, MELD Model for end-stage liver disease
